Literature DB >> 12244135

Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ligand-deficient mice.

Helga Schneider1, Didier A Mandelbrot, Rebecca J Greenwald, Fai Ng, Robert Lechler, Arlene H Sharpe, Christopher E Rudd.   

Abstract

Although CTLA-4 (CD152) has potent inhibitory effects on T cell function, the signaling events affected by this coreceptor remain to be fully defined. Mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) act as crucial regulators of multiple aspects of cell function. Ab ligation studies have reported an inhibitory effect of CTLA-4 on TCR-induced ERK and JNK activation. In this study, we have re-examined the specificity of CTLA-4 inhibition of MAPKs by using natural ligand with ex vivo-purified CD4(+) T cells deficient in CD80 and CD86 (double knockout), or CTLA-4, CD80, and CD86 (triple knockout). Under these conditions, CTLA-4 ligation was found to up-regulate and sustain JNK activation, while inhibiting ERK activity. At the same time, JNK activation could not account for CTLA-4 induction of TGF-beta production. Our findings demonstrate that CTLA-4 cosignaling is more complex than previously appreciated, with an ability to differentially regulate members of the MAPK family in T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244135     DOI: 10.4049/jimmunol.169.7.3475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.

Authors:  Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-26       Impact factor: 11.205

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

4.  The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.

Authors:  Melanie Stumpf; Xuyu Zhou; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

Review 5.  Immunotherapy for lung cancer: for whom the bell tolls?

Authors:  Pedro Madureira; Ramon Andrade de Mello; Alessandro de Vasconcelos; Yan Zhang
Journal:  Tumour Biol       Date:  2015-03-04

6.  CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function.

Authors:  Helga Schneider; Elke Valk; Silvy da Rocha Dias; Bin Wei; Christopher E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-26       Impact factor: 11.205

7.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 8.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 9.  Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions.

Authors:  Philip J S Stork; Tara J Dillon
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

Review 10.  TGF-beta: how tolerant can it be?

Authors:  Sharon M Wahl; Wanjun Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.